Clinical implications of JUPITER in a contemporary European population: the EPIC-Norfolk prospective population study

European Heart Journal

Volumn 34, Issue 18, 2013, Pages 1350-1357

  Sondermeijer, Brigitte M ^a   Boekholdt, S Matthijs ^a   Rana, Jamal S ^b   Kastelein, John J P ^a   Wareham, Nicholas J ^c   Khaw, Kay Tee ^c  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b Kaiser Permanente Northern California ^*  (United States)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

C reactive protein; Coronary heart disease; Low density lipoprotein cholesterol

Indexed keywords

C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; COHORT ANALYSIS; DISEASE CLASSIFICATION; FEMALE; FOLLOW UP; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RISK ASSESSMENT; WAIST CIRCUMFERENCE;

C-REACTIVE PROTEIN; CORONARY HEART DISEASE; LOW-DENSITY LIPOPROTEIN CHOLESTEROL;

AGED; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; CORONARY DISEASE; ENGLAND; FEMALE; FLUOROBENZENES; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PATIENT SELECTION; PROSPECTIVE STUDIES; PYRIMIDINES; RISK ASSESSMENT; SULFONAMIDES;

EID: 84877790930     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/eht047     Document Type: Article

References (15)

1. Mora S, Wenger NK, DeMicco DA, Breazna A, Boekholdt SM, Arsenault BJ, Deedwania P, Kastelein JJP, Waters DD. Determinants of residual risk in secondary prevention patients treated with high- versus low-dose statin therapy/clinical perspective. Circulation 2012;125:1979-1987
2. Libby P. The forgotten majority: Unfinished business in cardiovascular risk reduction. J Am Coll Cardiol 2005;46:1225-1228
3. Ridker PM, Danielson E, Fonseca FAH, Genest J, Gotto AM, Kastelein JJP, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ. Rosuvastatin to prevent vascular events in men and women with elevated c-reactive protein. N Engl J Med 2008;359:2195-2207
4. Michos ED, Blumenthal RS. Prevalence of low low-density lipoprotein cholesterol with elevated high sensitivity c-reactive protein in the US: Implications of the JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin) Study. J Am Coll Cardiol 2009;53:931-935
5. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, Gotto AM. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001;344:1959-1965
6. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002;347:1557-1565
7. Yang EY, Nambi V, Tang Z, Virani SS, Boerwinkle E, Hoogeveen RC, Astor BC, Mosley TH, Coresh J, Chambless L, Ballantyne CM. Clinical implications of JUPITER (Justification for the Use of statins in Prevention: An Intervention Trial Evaluating Rosuvastatin) in a U.S. population: Insights from the ARIC (Atherosclerosis Risk in Communities) study. J Am Coll Cardiol 2009;54:2388-2395
8. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel iii). JAMA 2001;285:2486-2497
9. Day N, Oakes S, Luben R, Khaw KT, Bingham S, Welch A, Warenham N. EPICNorfolk: Study design and characteristics of the cohort. European Prospective Investigation of Cancer. Br J Cancer 1999;80:95-103
10. Wilson PWF, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-1847
11. Spatz ES, Canavan ME, Desai MM. From here to JUPITER identifying new patients for statin therapy using data from the 1999-2004 National Health and Nutrition Examination Survey. Circ Cardiovasc Qual Outcomes 2009;2:41-48
12. Rocha VZ, Libby P. Obesity, inflammation, and atherosclerosis. Nat Rev Cardiol 2009;6:399-409
13. Ridker PM, MacFadyen JG, Nordestgaard BG, Koenig W, Kastelein JJP, Genest J, Glynn RJ. Rosuvastatin for primary prevention among individuals with elevated high-sensitivity C-reactive protein and 5-10% and 10-20% 10-year risk: Implications of the Justification for Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial for intermediate risk. Circ Cardiovasc Qual Outcomes 2010;3:447-452
14. Ridker PM. High-sensitivity C-reactive protein and cardiovascular risk: Rationale for screening and primary prevention. Am J Cardiol 2003;92:17-22
15. Everett BM, Kurth T, Buring JE, Ridker PM. The relative strength of C-reactive protein and lipid levels as determinants of ischemic stroke compared with coronary heart disease in women. J Am Coll Cardiol 2006;48:2235-2242